BMYBristol Myers Squibb
Is the business good?
The checks split: 8 of 9 health tests passed and earnings fully cash-backed (1.4×), but returns that lean on debt.
High fundamental quality. Nine pass/fail tests of year-over-year health from the filings.
Operating profit is fully backed by cash. Conversion is worsening vs a year ago.
Positive operating leverage, operating profit is growing faster than sales, so margins widen as the business scales.
Leverage-amplified, a high assets-to-equity ratio does much of the work. ROE 37% = margin × turnover × leverage.
Unless marked, from derived.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is BMY?
Bristol Myers Squibb earns 17% on the capital it employs against a 9.0% cost of capital, so the business is worth more the bigger it gets.
Return on invested capital · cost of capital 9.0% · 8.1 points above what the capital costs: growth creates value
- Operating margin
- 24%
Operating margin · Drug Manufacturers - General median 24% · 12 months to Q2 2026
- Cash conversion
- 1.38×
Cash conversion · 3.14× a year ago · operating cash flow covers the operating profit after tax
- Share count, year on year
- +0.49%
Share count, year on year · flat: no meaningful dilution
| Year | Operating margin |
|---|---|
| FY2020 | −16% |
| FY2021 | 17% |
| FY2022 | 17% |
| FY2023 | 19% |
| FY2024 | −17% |
| FY2025 | 19% |
Details›
- Gross margin12 months to Q2 2026
- 70%
- Operating margin12 months to Q2 2026
- 24%
- Net margin12 months to Q2 2026
- 19%
- Free cash flow margin
- 23%
- R&D as % of revenue
- 22%
- Revenue, trailing twelve months
- $49.2B
- Free cash flow, trailing twelve months
- $11.4B
- Net income, trailing twelve months
- $9.28B
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- 17%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Drug Manufacturers, General
The closest names by size in the same industry